Stocksigma LogoStocksigma Logo

CORONA Remedies Reports Strong Q2FY27 Results Outpacing Indian Pharma Market Growth

CORONA Remedies reported 22.2% YoY revenue growth to ₹441.2 Cr in Q2FY27, outpacing IPM growth by 1.9x for MAT Sep'26

CORONA Remedies Reports Strong Q2FY27 Results Outpacing Indian Pharma Market Growth

Corona Remedies Ltd · Press Release · 31 Oct 2026, 12:16 am

CORONA Remedies Reports Strong Q2FY27 Results Outpacing Indian Pharma Market Growth CORONA Remedies reported 22.2% YoY revenue growth to ₹441.2 Cr in Q2FY27, outpacing IPM growth by 1.9x for MAT Sep'26. EBITDA rose 22.3% YoY to ₹96.0 Cr with stable margins at 21.7%, while PAT increased 15.3% YoY to ₹60.3 Cr, impacted by higher depreciation and amortization from newly commissioned facilities and brand acquisitions. Chronic and semi-chronic therapies contributed 71.2% to revenue. Additionally, the company secured Brazil's ANVISA GMP certification for its Bhayla facility covering oral solids and women's hormone production lines.

Original exchange filing (PDF)

More announcements from Corona Remedies Ltd

All Corona Remedies Ltd announcements